Pharmaceuticals

JIUDIAN PHARMACEUTICAL

Jiudian Pharmaceutical released FY2025 earnings on April 24 After-Market (BJT), actual revenue CNY 3.111 B (forecast CNY 3.281 B), actual EPS CNY 0.95 (forecast CNY 1.27)

JIUDIAN PHARMACEUTICAL released FY2026 Q1 earnings on April 24 After-Market BJT, actual revenue CNY 595.24 M, actual EPS CNY 0.11

JIUDIAN PHARMACEUTICAL released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 842.86 M, actual EPS CNY 0.1374

Jiudian Pharmaceutical FY2026 Q1 Earnings Release on April 25 After-Market BJT

JIUDIAN PHARMACEUTICAL to release FY2025 earnings on April 25 After-Market BJT, forecast revenue CNY 3.281 B, EPS CNY 1.27

JIUDIAN PHARMACEUTICAL released FY2025 9 Months earnings on October 29 Pre-Market (BJT), actual revenue CNY 2.268 B, actual EPS CNY 0.7936

JIUDIAN PHARMACEUTICAL released FY2025 Q3 earnings on October 29 Pre-Market (BJT), actual revenue CNY 756.09 M, actual EPS CNY 0.2135

Jiudian Pharmaceutical FY2025 Q3 Earnings Release on October 30, Pre-Market BJT

JIUDIAN PHARMACEUTICAL released FY2025 Semi-Annual earnings on August 22 After-Market (BJT), actual revenue CNY 1.512 B, actual EPS CNY 0.58

JIUDIAN PHARMACEUTICAL released FY2025 Q2 earnings on August 22 After-Market (BJT), actual revenue CNY 815.92 M, actual EPS CNY 0.3301

JIUDIAN PHARMACEUTICAL to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Jiudian Pharmaceutical Forecasts 10%-20% Growth in 2025

Jiudian Pharmaceutical Developing a Category 1 Traditional Chinese Medicine Innovation Drug

Jiudian Pharmaceutical Receives Registration Certificate for Stomach Ulcer Treatment Drug

Nine Star Pharmaceutical's Executive Bear Ying Reduces Shares

Jiudian Pharmaceutical's PDX-04 Receives Clinical Trial Approval

Jiudian Pharmaceutical's executive Xiong Ying reduced shareholding

Jiudian Pharmaceutical Collaborates with Zhongsheng Quanpei for Innovative Drug R&D

Jiudian Pharmaceutical Obtains Lidocaine Gel Patch Drug Registration Certificate

Jiudian Pharmaceutical Receives Notice of Approval for Drug Supplement Application

002511

300174

159787

300705

On the first trading day of the Year of the Horse, several listed companies announced their repurchase and increase plans and progress, including the repurchase plans of C&S and YUANLI ACTIVE CARBON, as well as the increase plans of CONCH CEMENT and HHP. Companies such as JIUDIAN PHARMACEUTICAL and Ningbo Sunrise also updated their repurchase progress

Wallstreetcn

YUANLI ACTIVE CARBON

E Fund CSI All Share Building Materials ETF

CONCH CEMENT

Fullgoal CSI 1000 Enhanced Index Fund(LOF)-A

Ningbo Sunrise

Fullgoal CSI All Share Building Materials ETF

Guotai CSI All Share building Materials ETF

On the first trading day of the Year of the Horse, the trend of share repurchases and increases in holdings by A-share listed companies continues

According to the Qichacha APP, recently, Hunan JIUDIAN SHANNUO Innovative Pharmaceutical Technology Co., Ltd. was established, with Zhu Zhihong as the legal representative and a registered capital of 100 million yuan. The business scope includes: medical research and experimental development; engineering and technology research and experimental development, etc. Qichacha's equity penetration shows that the company is jointly held by JIUDIAN PHARMACEUTICAL, Changsha Xiangjiang Shannuo Venture Capital Partnership, and others

Zhitong

JIUDIAN PHARMACEUTICAL and others establish an innovative pharmaceutical technology company

According to the Zhitong Finance APP, JIUDIAN PHARMACEUTICAL released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 2.268 billion yuan, a year-on-year increase of 5.69%. The net profit attributable to shareholders of the listed company was 406 million yuan, a year-on-year decrease of 9.64%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 391 million yuan, a year-on-year decrease of 6.47%. The basic earnings per share were 0.82 yuan

JIUDIAN PHARMACEUTICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 406 million yuan, a decrease of 9.64%

According to the Qichacha APP, recently, Hunan Ginseng Manman E-commerce Co., Ltd. was established, with Zheng Liang as the legal representative. The business scope includes: retail of cosmetics; internet sales; advertising design and agency; brand management, etc. Qichacha's equity penetration shows that the company is wholly owned by JIUDIAN PHARMACEUTICAL

JIUDIAN PHARMACEUTICAL established a ginseng e-commerce company in Hunan

JIUDIAN PHARMACEUTICAL announced that the company plans to use its own funds of 50 million yuan to jointly invest with Changsha Xiangjiang Shannuo Venture Capital Partnership and Hainan Jiu Zhi Qing Yan Technology Partnership to establish Hunan Jiu Dian Shannuo Innovative Pharmaceutical Technology Co., Ltd. The registered capital of Jiu Dian Shannuo is 100 million yuan, with the company holding 50%, Xiangjiang Shannuo holding 30%, and Jiu Zhi Qing Yan holding 20%. This investment constitutes a related party transaction but does not constitute a major asset reorganization

JIUDIAN PHARMACEUTICAL: Plans to use its own funds of 50 million yuan to jointly invest with Xiangjiang Shannuo and Jiu Zhi Qing Yan to establish Hunan Jiu Dian Shannuo Innovative Pharmaceutical Technology Co., Ltd

According to the Zhitong Finance APP, JIUDIAN PHARMACEUTICAL announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. After completing the relevant preparatory work, it will carry out clinical trial research. The approved clinical trials include: JIZM01 for clinical trials of closed soft tissue contusions and joint sprains, and JIZM02 for clinical trials of shoulder periarthritis

JIUDIAN PHARMACEUTICAL has been approved to conduct clinical trials for two drugs

688553

002422

300111

688221

The chemical pharmaceutical sector rose in early trading, with SUNFLOWER hitting the daily limit of a 20cm increase, followed by gains in Froniter Biotechnologies, HUIYU PHARMACEUTICAL, JIUDIAN PHARMACEUTICAL, KELUN PHARMA, and Yuandong Biotech

HUIYU PHARMACEUTICAL

KELUN PHARMA

SUNFLOWER

Froniter Biotechnologies

The chemical pharmaceutical sector rose in early trading, with SUNFLOWER hitting the daily limit of a 20cm increase

On September 12th, JIUDIAN PHARMACEUTICAL stated during an institutional research meeting that based on the current research and development progress, the JIJ02 gel is expected to complete Phase I clinical trials in the first half of next year and initiate Phase II clinical trials

JIUDIAN PHARMACEUTICAL: The JIJ02 gel is expected to complete Phase I clinical trials in the first half of next year

JIUDIAN PHARMACEUTICAL recently announced the summary report of the Phase III clinical trial for the Jiaoqi Pain Relief Gel Patch, showing that the drug is significantly effective in improving knee osteoarthritis pain. The experimental group outperformed the placebo group on multiple indicators, and the safety profile is good. The company will continue to advance the registration application and will launch sales upon approval

JIUDIAN PHARMACEUTICAL: The Phase III clinical trial report for Jiaoqi Pain Relief Gel Patch has been released

According to the Zhitong Finance APP, JIUDIAN PHARMACEUTICAL released its semi-annual report for 2025, showing an operating income of 1.512 billion yuan, a year-on-year increase of 10.67%. The net profit attributable to shareholders of the listed company was 291 million yuan, a year-on-year increase of 2.57%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 283 million yuan, a year-on-year increase of 10.74%. The basic earnings per share were 0.59 yuan

JIUDIAN PHARMACEUTICAL released its performance for the first half of the year, with a net profit attributable to the parent company of 291 million yuan, an increase of 2.57%

JIUDIAN PHARMACEUTICAL(300705.SZ)